60 Degrees Pharmaceuticals (SXTP) Free Cash Flow (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Free Cash Flow of -$2.8 million for Q1 2026, down 73.22% year-over-year from -$10.3 million in Q1 2025, and down 56.38% quarter-over-quarter from -$1.8 million in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Free Cash Flow (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Free Cash Flow for 5 consecutive years, with -$2.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 73.22% year-over-year to -$2.8 million; the TTM figure through Mar 2026 stood at -$8.2 million (down 31.39% YoY), while the FY2025 annual figure was -$7.0 million, down 21.51% from the prior year.
- Free Cash Flow eased to -$2.8 million in Q1 2026 per SXTP's latest filing, from -$1.8 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$97552.0 in Q4 2022 and bottomed at -$3.7 million in Q3 2023.
- Historically, Free Cash Flow has averaged -$1.4 million across 5 years, with a median of -$1.5 million in 2025.
- On a YoY basis, Free Cash Flow climbed as much as 54.67% in 2024 and fell as far as 1271.26% in 2024.
- 60 Degrees Pharmaceuticals' Free Cash Flow stood at -$97552.0 in 2022, then retreated by 22.47% to -$119468.0 in 2023, then tumbled by 1271.26% to -$1.6 million in 2024, then slipped by 8.19% to -$1.8 million in 2025, then tumbled by 56.38% to -$2.8 million in 2026.
- Business Quant data shows SXTP's Free Cash Flow at -$2.8 million in Q1 2026, -$1.8 million in Q4 2025, and -$2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | -2.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.77 Mn |
| Mar 31, 2026 | -2.77 Mn |
| Dec 31, 2025 | -1.77 Mn |
| Dec 31, 2025 | -1.77 Mn |
| Sep 30, 2025 | -2.12 Mn |
| Sep 30, 2025 | -2.12 Mn |
| Jun 30, 2025 | -1.50 Mn |
| Jun 30, 2025 | -1.50 Mn |
| Mar 31, 2025 | -1.60 Mn |
| Mar 31, 2025 | -1.60 Mn |
| Dec 31, 2024 | -1.64 Mn |
| Dec 31, 2024 | -1.64 Mn |
| Sep 30, 2024 | -1.69 Mn |
| Sep 30, 2024 | -1.69 Mn |
| Jun 30, 2024 | -1.28 Mn |
| Jun 30, 2024 | -1.28 Mn |
| Mar 31, 2024 | -1.14 Mn |
| Mar 31, 2024 | -1.14 Mn |
| Dec 31, 2023 | -119,468.00 |
| Dec 31, 2023 | -119,468.00 |